September 2025 in “Figshare” Alopecia areata involves complex immune activity, mainly Th1, with potential benefits from broader immune treatments.
CD4 T cells need IFN-γ to cause hair loss in alopecia areata.
March 2025 in “Drug Development Research” The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.
April 2024 in “Biosaintifika Journal of Biology & Biology Education” A gel from stem cells can reduce baldness caused by fluconazole in rats.
November 2023 in “Journal of Investigative Dermatology” Highly active but fewer CD14+CD16- monocytes are found in Alopecia Areata patients, regardless of severity.
April 2021 in “Sohag Medical Journal” Alopecia areata is an autoimmune condition causing hair loss, linked to genetic factors and immune system issues, with no cure yet.
January 2016 in “Human & Experimental Toxicology” A specific DNA sequence caused hair loss in male mice by activating immune cells and increasing a certain immune signal.
January 2018 in “Indian Dermatology Online Journal” DM and AA may share a common cause.
1 citations
,
May 2023 in “The Journal of Immunology” CD4 T cells can cause alopecia areata by activating CD8 T cells to attack hair follicles.
253 citations
,
April 2009 in “Journal of Biological Chemistry” p2y5, now called LPA6, is a receptor important for human hair growth.
December 2025 in “International Journal of Innovative Technologies in Social Science” Alcohol and nicotine harm skin health and speed up aging.
COVID-19 might cause gray hair to regain color.
January 2024 in “Advanced Healthcare Materials” Using a special gel with copper and curcumin along with a scraping massage technique improved hair growth better than the common hair loss treatment, minoxidil.
48 citations
,
September 2020 in “Frontiers in Immunology” Loss of OGG1 increases skin inflammation and auto-antibodies in lupus.
106 citations
,
January 2013 in “Clinical and Developmental Immunology” Alopecia areata is caused by immune system attacks on hair follicles, often triggered by viral infections.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
47 citations
,
March 2019 in “Journal of immunology research” Valproic Acid could potentially be used to treat immune-related conditions due to its ability to modify immune cell functions.
3 citations
,
November 2020 in “Journal of The American Academy of Dermatology” The document suggests that more research is needed to confirm if baldness can indicate a higher risk of severe COVID-19 in men.
5 citations
,
July 2023 in “International Journal of Women’s Dermatology” Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.
December 2023 in “American journal of medical genetics. Part A” A new syndrome was linked to two new genetic changes in the MBTPS1 gene in a 14-year-old girl.
January 2022 in “Faculty of 1000 Research Ltd” Understanding molecular mediators can improve skin healing treatments.
October 2021 in “International journal of basic and clinical pharmacology” Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
Somatostatin helps hair follicles suppress immune responses, which might aid in treating certain hair loss conditions.
13 citations
,
October 2021 in “The Journal of Microbiology” Human placenta hydrolysate may help treat COVID-19 by reducing virus replication and boosting immune response.
52 citations
,
September 2022 in “Viruses” SARS-CoV-2 proteins help the virus avoid the immune system, delaying response and increasing inflammation.
12 citations
,
March 2016 in “Experimental Dermatology” Hand preference and sexual orientation may predict finasteride side effects in male hair loss.
9 citations
,
September 2017 in “PubMed” EGFR inhibitors can cause skin issues, but managing them is important for treatment success.
5 citations
,
December 2022 in “Genes” Genetic differences affect how people respond to COVID-19.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
44 citations
,
August 1996 in “Drugs & Aging” Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.